SK Life Science

Executive Summary

SK Life Science, Inc. is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders and oncology. Founded in 2000 and headquartered in Paramus, New Jersey, the company is dedicated to addressing unmet medical needs through the discovery and development of novel therapies. Its most notable product is cenobamate (Xcopri®), an antiseizure medication approved for partial-onset seizures in adults. SK Life Science continues to expand its CNS pipeline, including efforts to develop cenobamate for pediatric indications and other seizure types, as well as exploring oncology candidates. The company's mission is to connect health with happiness by bringing meaningful treatments to patients. SK Life Science operates as a key subsidiary of SK Group, leveraging its parent company's resources to advance its pipeline. While the company has established a commercial foothold with Xcopri, the next few years will be critical for demonstrating pipeline depth and securing additional approvals. Key upcoming catalysts include potential label expansions for cenobamate, data readouts from ongoing Phase 3 trials, and early-stage oncology updates. Given the competitive CNS landscape, execution on these milestones will be essential for the company's growth trajectory.

Upcoming Catalysts (preview)

• Q2 2027FDA Decision on Cenobamate for Pediatric Epilepsy65% success
• Q4 2026Phase 3 Topline Data for Cenobamate in Generalized Tonic-Clonic Seizures70% success
• Q3 2026Initial Phase 1/2 Oncology Data Readout40% success